Background-Platelet activation at sites of vascular injury is essential for hemostasis, but it is also a major pathomechanism underlying ischemic injury. Because anti-inflammatory therapies limit thrombosis and antithrombotic therapies reduce vascular inflammation, we tested the therapeutic potential of 2 proresolving endogenous mediators, annexin A1 N-terminal derived peptide (AnxA1 ) and aspirin-triggered lipoxin A 4 (15-epi-lipoxin A 4 ), on the cerebral microcirculation after ischemia/reperfusion injury. Furthermore, we tested whether the lipoxin A 4 receptor formyl-peptide receptor 2/3 (Fpr2/3; ortholog to human FPR2/lipoxin A 4 receptor) evoked neuroprotective functions after cerebral ischemia/reperfusion injury. Methods and Results-Using intravital microscopy, we found that cerebral ischemia/reperfusion injury was accompanied by neutrophil and platelet activation and neutrophil-platelet aggregate formation within cerebral microvessels. Moreover, aspirin-triggered lipoxin A 4 activation of neutrophil Fpr2/3 regulated neutrophil-platelet aggregate formation in the brain and inhibited the reactivity of the cerebral microvasculature. The same results were obtained with AnxA1 administration. Blocking Fpr2/lipoxin A 4 receptor with the antagonist Boc2 reversed this effect, and treatments were ineffective in Fpr2/3 knockout mice, which displayed an exacerbated disease severity, evidenced by increased infarct area, blood-brain barrier dysfunction, increased neurological score, and elevated levels of cytokines. Furthermore, aspirin treatment significantly reduced cerebral leukocyte recruitment and increased endogenous levels of aspirin-triggered lipoxin A 4 , effects again mediated by Fpr2/3. Conclusion-Fpr2/lipoxin A 4 receptor is a therapeutic target for initiating endogenous proresolving, anti-inflammatory pathways after cerebral ischemia/reperfusion injury. to play an active role in returning local sites of inflammation to homeostasis. 2-4 These proresolving mediators act at different phases of the inflammatory response and are involved in blockade of leukocyte recruitment, inhibition of cytokine release, promotion of apoptosis, stimulation of phagocytosis, and decreasing vascular permeability.
I
nflammation plays a crucial role in the pathophysiological cascade of ischemic stroke and related forms of brain injury. 1 Although the exact mechanisms responsible for postischemic cerebral damage are not fully understood, increasing evidence suggests the inflammatory state after ischemia/ reperfusion (I/R) as a crucial contributing factor to these pathogenic processes. It has been demonstrated that post-I/R inflammation results in endothelial cell activation and consequent recruitment and activation of leukocytes and platelets, leading to further cerebral microvascular dysfunction and subsequent tissue injury. 1 Because the brain is highly susceptible to I/R injury, prevention of cerebral ischemic events has become a major part of modern health care. However, neuronal cells have a limited capacity for restoration after cerebral I/R; therefore, there is an unmet clinical need to explore novel therapeutic avenues to better resolve the aggressive inflammatory state after cerebral ischemic insults to limit the irrecoverable neuronal damage.
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It is now appreciated that inflammatory mechanisms do not disperse spontaneously but rather that resolution of inflammation involves a tightly orchestrated series of events, engaging specific endogenous mediators and protective pathways. 2 Among these, annexin A1 (AnxA1) and its N-terminal peptide AnxA1 (Ac-AMVSEFLKQAWFIENEEQEYVQTVK), the eicosanoidderived lipoxin A 4 (LXA 4 ), and 15(R)-epi-lipoxin A 4 (referred to as aspirin-triggered lipoxin [ATL] and produced after aspirin acetylation of inducible cyclooxygenase-2) have been shown to play an active role in returning local sites of inflammation to homeostasis. [2] [3] [4] These proresolving mediators act at different phases of the inflammatory response and are involved in blockade of leukocyte recruitment, inhibition of cytokine release, promotion of apoptosis, stimulation of phagocytosis, and decreasing vascular permeability. 3, 4 Effectors of resolution ensure that these responses remain localized within the inflamed tissue and are extinguished within an adequate timeline. Of relevance, both AnxA1/AnxA1 Ac2-26 and LXA 4 /ATL mediate their effects through a common G protein-coupled receptor: the formyl peptide receptor 2 (Fpr2/3), also called lipoxin A 4 receptor (ALX). 5 This receptor is expressed on a variety of cell types such as endothelial cells and myeloid lineages, 6 for example, neutrophils, which are involved in the inflammation observed in early stages of reperfusion after ischemic insults.
Several lines of evidence, produced by our group and others, indicate protective effects of these proresolving mediators in a number of post-I/R events, including in the mesentery, 7, 8 heart, 9 lung, 10 and kidney. 11 We have previously shown that AnxA1/ AnxA1 Ac2-26 , LXA 4 , and ATL mediate their effects through Fpr2/ ALX in a global murine stroke model (a model that mimics human stroke after atherosclerotic degeneration of the common carotid arteries and respiratory or cardiac arrest). 12 In a focal I/R model (the middle cerebral artery occlusion + reperfusion [MCAo/R] model), we reported that exogenous administration of AnxA1 markedly attenuated I/R injury by acting on a member of the FPR family, which at the time we speculated to be Fpr2/ ALX, 12 although this possibility was never confirmed until now. Here, we demonstrate a novel role of AnxA1 and ATL in regulating leukocyte-platelet responses in the cerebral microvasculature after I/R as attained with pharmacological blockade, quantifying endogenous mediator levels, and using Fpr2/3 −/− mice. We present novel evidence that specifically neutrophil Fpr2/3 regulates cerebral neutrophil-platelet aggregation (NPA) by rapid generation of ATL in an endogenous biosynthetic circuit to resolve inflammation and to restore homeostasis. In summary, Fpr2/ALX is a therapeutic target for initiating endogenous proresolving, anti-inflammatory pathways after cerebral I/R injury.
Methods
A detailed Methods section is provided in the online-only Data Supplement. Boc2 (N-tert-butoxycarbonyl-L-Phe-D-Leu-L-Phe-D-Leu-LPhe, MPBiomedicals, Cambridge, UK) 10 µg per mouse, 13 and ATL (stable epimer of LXA 4 ) 4.0 μg per mouse 12 were administered (100 µL) intravenously at the start of cerebral reperfusion. In a separate set of experiments, mice were intraperitoneally treated with aspirin (ASA; 150 mg/kg, Sigma-Aldrich, Dorset, UK) 60 minutes before I/R.
Animals

Middle Cerebral artery Occlusion + Reperfusion (MCAo/R) Model
MCAo was performed for 60 minutes followed by 4 or 24 hours of reperfusion according to standard operating procedure in our laboratory. 13 
Blood Sampling and Cell Counts
Blood samples were taken before and after MCAo for measuring leukocytes (3% citric acid and 10% crystal violet) and platelet (1% buffered ammonium oxalate) counts with a hemocytometer.
Platelet and Leukocyte Labeling
Platelets were isolated from donor mice, labeled with carboxyfluorescein succinimidyl ester (CFSE 90 µmol/L, 10 minutes, SigmaAldrich) and injected into recipient mice, followed by 0.02% rhodamine 6G (Sigma-Aldrich) to label circulating leukocytes.
14
Cerebral Intravital Fluorescence Microscopy
Intravital fluorescence microscopy (IVM) was performed with a Zeiss Axioskop microscope (Zeiss, New York, NY) 12, 13 (see the online-only Data Supplement).
Infarct Volume
After 24 hours of reperfusion, brains were removed and stained with 2% 2,3,5-triphenyltetrazolium chloride (Sigma Aldrich). Sections were photographed, and the digitized images of each brain section (and the infarcted area) were quantified with NIH 1.57 Image Software.
13
Neurological Score
A five-point neurological deficit score (NS) was used: 0=no deficit, 1=failure to extend the right paw, 2=circling to the right, 3=falling to the right, and 4=unable to walk spontaneously.
14
Blood-Brain Barrier Dysfunction
Blood-brain barrier (BBB) permeability was assessed with Evans blue extravasation. 15 BBB permeability was normalized by dividing tissue Evans blue concentration (μg/g brain weight) by plasma concentration (μg/mL).
passed the normality assumption were analyzed with the Student t test (2 groups) or ANOVA with Bonferroni posttests (>2 groups), which were performed with GraphPad Prism5 software. Data that failed the normality assumption were analyzed with the nonparametric Mann-Whitney U test (2 groups) −/− demonstrated an increase in both leukocyte and platelet adhesion (P<0.0001 for both) compared with WT mice ( Figure 1A and 1B). Figure 1C and 1D illustrates representative images of cerebral venules from sham, I/R WT, and Fpr2/3 −/− mice at 24 hours, displaying the marked accumulation of leukocytes and platelets (Figure 1E and 1F Figure 2A and 2B. Although after 4 hours of reperfusion differences were noted between sham and I/R, no changes were noted between the genotypes (data not shown). However, NSs assessed after 24 hours of reperfusion were significantly worse in Fpr2/3 −/− than in WT mice (Figure 2A ), a response that correlated with elevated IVs (Figure 2B ). No significant differences among mouse genotypes were detected with respect to the hemodynamic parameters under assessment ( Table I in ) mice after ischemia/reperfusion (I/R). Wild-type (WT; C57BL/6) and Fpr2/3 −/− mice were subjected to middle cerebral artery occlusion for 60 minutes followed by 4 or 24 hours of reperfusion. Leukocyte and platelet recruitment in the cerebral microcirculation was quantified in terms of (A) the number of adherent leukocytes (cells stationary ≥30 seconds) and (B) the number of adherent platelets (cells stationary for ≥2 seconds). Representative intravital fluorescence microscopy video stills at 24 hours showing few cellular interactions in the cerebral microcirculation of (C) WT Figure 2C ). Furthermore, we found a marked increase in myeloperoxidase (a marker of neutrophil activation) after I/R, which again was significantly higher in Fpr2/3 −/− mice ( Figure 2D ). All mice undergoing MCAo/R had decreased white blood cell counts, which was reflected by a decrease in lymphocyte count. The neutrophil count was increased in MCAo/R mice and further exacerbated in MCAo/R Fpr2/3 −/− mice compared with WT MCAo/R mice (Table) . No differences were noted in platelet count (Table) , the relative proportions of immature versus mature platelets (Figure IA and IB in the online-only Data Supplement), 18, 19 or the level of activation within these populations ( Figure IC and ID in the online-only Data Supplement) 20 in any groups or genotypes.
Finally, we determined serum and tissue cytokine levels. All cytokines (except interleukin [IL]-10) measured in plasma of WT mice were elevated after I/R compared with sham mice (data not shown), whereas in the brain homogenates, MCAo/R elicited discrete increases in tumor necrosis factor-α (TNFα), CCL2, and 
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IL-6 compared with sham mice (data not shown). When comparing WT and Fpr2/3 −/− mice subjected to MCAo for 60 minutes followed by 24 hours of reperfusion, we found that that absence of Fpr2/3 −/− resulted in heightened serum levels of IL-1β and TNFα (Figure 3A and 3B) with no significant difference in CCL2, IL-10, and IL-6 levels compared with WT mice (Figure 3C-3E ).
Local cytokine levels (TNFα, CCL2, and IL-6) were significantly elevated in the left (injured) hemisphere of WT and Fpr2/3 −/− mice after I/R ( Figure 3G , 3H, and 3J). Moreover, both TNFα and IL-1β levels were more elevated in Fpr2/3 −/− mice than in WT mice. IL-10 levels were decreased in Fpr2/3 −/− mice compared with WT mice. No cytokine was above control values in the contralateral hemisphere of either WT or Fpr2/3 −/− mice (except IL-10), suggesting that these inflammatory mechanisms are confined to the ischemic region (ie, ipsilateral side).
Fpr2/3 −/− Mice Have Reduced Cerebral NPAs
Once stimulated at sites of inflammation, activated platelets are prone to adhering to neutrophils, forming circulating NPAs, a mechanism that has been demonstrated in ischemic stroke. 21 Because the IVM data suggested an augmented platelet activation in Fpr2/3 −/− mice ( Figure 1B ), we further investigated the state of activation in platelets after cerebral I/R injury by measuring the thromboxane A 2 metabolite thromboxane B 2 , which is a soluble marker for platelet activation. Plasma levels of stable thromboxane B 2 were increased in both WT and Fpr2/3 −/− mice after I/R and further elevated in the absence of Fpr2/3 when we compared I/R groups with each other (Figure 4A ). We then assessed the potential of these activated platelets to form aggregates. By using fluorescence IVM, we revealed a dynamic formation of NPAs within the brain microcirculation, showing intravascular neutrophils interacting with platelets ( Figure 4B) . Surprisingly, we found that Fpr2/3 −/− mice subjected to MCAo for 60 minutes followed by 24 hours of reperfusion had significantly fewer NPAs than WT mice ( Figure 2C ). Although the IVM data had shown an increase in total adherent leukocyte counts in Fpr2/3 −/− mice compared with WT mice, we found that ≈33% of these were platelet bearing in Fpr2/3 −/− mice compared with ≈60% platelet-bearing leukocytes in WT mice (No significant differences were measured between WT and Fpr2/3 −/− mice in sham conditions).
Next, it was important to ascertain whether platelet or neutrophil Fpr2/3 was functional in these settings. Data in Figure 4D show that after I/R CSFE-labeled platelets from Fpr2/3 −/− mice injected into WT animals led to numbers of NPAs similar to those quantified with WT platelets transferred into WT recipients. Thus, NPA formation in WT animals was independent of the presence of Fpr2/3 on the infused platelets. In addition, lower aggregate numbers were found when platelets from WT or Fpr2/3 −/− mice were injected into Fpr2/3 −/− mice subjected to I/R ( Figure 4D ), demonstrating that NPA formation in Fpr2/3 −/− mice was also independent from the type of transferred platelets. Thus, these findings reveal that it is not the platelet Fpr2/3 that is important in NPA formation but rather a functional neutrophil Fpr2/3.
Fpr2/3 Agonists Attenuate I/R-Induced Cerebrovascular Injury in WT Mice
Having demonstrated an exacerbated cerebral inflammatory response in mice lacking Fpr2/3, coupled with the importance for a functional neutrophil Fpr2/3, we next tested the protective potential of targeting FPR2/ALX in stroke. Treating WT mice with either AnxA1 Ac2-26 or ATL markedly attenuated the inflammatory response, as assessed by NS, IVM, and IV (Figure II , respectively). These protective effects translated to reduced IV (17.2±1.3% versus 25.3±1.2% in saline-treated mice) and NS (1.5±0.2 versus 2.9±0.2). Similar effects were produced with ATL, decreasing leukocyte adhesion by 35%, platelet adhesion by 45%, IV by 42%, and NS by 58% compared with WT mice. When either compound was coadministered with the Fpr2/3 antagonist Boc2, there was a loss of effect (Figure II in the online-only Data Supplement), whereas the antagonist was ineffective when given alone.
Harnessing Endogenous Fpr2/3 Activation as a Therapeutic Strategy
Finally, we assessed whether a pharmacological dose of ASA (150 mg/kg) changed ATL levels in our stroke model. Plasma Figure 5A and 5B). Furthermore, ASA treatment reduced leukocyte adherence and NPAs in WT mice ( Figure 5C and 5D ). Next, we determined whether increased levels of endogenous ATL produced by ASA treatment contributed to the cerebroprotective effects that we observed. Administration of the Fpr2/3 antagonist Boc2 alone 15 had no effect on leukocyte adhesion and NPA formation. However, when administered in combination with ASA, it reversed the effects of ASA; that is, it increased leukocyte adhesion and NPA formation ( Figure 5C and 5D ). These pharmacological results were complemented by analysis in Fpr2/3 −/− mice. Despite the fact that administration of ASA to Fpr2/3 −/− and WT mice resulted in increased plasma and brain homogenate ATL concentrations ( Figure 5E and 5F), ASA was unable to reduce leukocyte adherence or NPAs in Fpr2/3 −/− mice ( Figure 5G and 5H) . Furthermore, we found that ASA was unable to reduce NS and IV in Fpr2/3 −/− mice but was able to do so in the WT counterparts (data not shown).
Discussion
There are several novel key findings from this study: (1) The absence of Fpr2/3 heightens the inflammatory response after cerebral I/R; (2) agonistic targeting of Fpr2/3 is protective in stroke; (3) ATL is required for ASA protection in cerebral I/R injury; and finally, (4) functional neutrophil Fpr2/3 is needed for formation of NPAs, through which ATL exerts its effects within the cerebral microvasculature (Figure 6 ).
Despite the positive effects of blocking various aspects of the inflammatory cascade, which ameliorates injury in experimental stroke, 20 there are currently few effective treatment options for patients affected by ischemic stroke. The second phase of inflammation is the resolution one in which active engagement of molecular and cellular circuits ensures termination. 5 Thus, endogenous anti-inflammatory mediators such as AnxA1 Ac2-26 and ATL could be exploited for guiding innovative drug discovery programs to develop compounds likely to be devoid of the major side effects associated with current anti-inflammatory and vasculoprotective therapies (eg, vomiting, nausea, constipation, diarrhea, ulcers, bleeding, organ [liver and kidney] failure) because their application would mimic a way that the body naturally disposes of inflammation. 22 These mediators target Fpr2/3; hence, we began here by assessing whether Fpr2/3 played functional roles in cerebral I/R. Fpr2/3 belongs to a receptor family of the hematopoietic/ myeloid cell population. Within this family, FPR1 is one of the best-studied G protein-coupled receptors, dating back to the ) exist in humans (and mice) with a wide tissue distribution; they interact with a number of structurally diverse, naturally occurring ligands that can promote opposing biological actions. 23 We demonstrate here that Fpr2/3 −/− mice (lacking the ortholog of FPR2/ALX) display an exacerbated cerebral inflammatory response after I/R injury. This was observed by increased adherent leukocytes and platelets, which is in keeping with the cerebral effects observed in other models (eg, systemic administration of lipopolysaccharide), 24 along with increased IV (which is inextricably linked to levels of inflammation during cerebral reperfusion) and NS. We also found that although there was a reduced circulating lymphocyte count in MCAo/R mice (which may account for the decrease in white blood cells and confirms findings from another group), 25 there was no difference between WT and Fpr2/3 −/− mice. However, the exacerbation detected in peripheral neutrophil counts in MCAo/R Fpr2/3 −/− compared with MCAo/R WT mice may account for the increased adherent neutrophils quantified in the brain microvasculature of these mice. These findings are in line with the experimental and clinical notion that supports the importance of neutrophil infiltration in ischemic stroke.
Previous focal I/R models have shown that the recruitment of neutrophils in the ischemic brain occurs within 30 minutes to a few hours and peaks in the first 3 days. 26 Furthermore, in the clinic, neutrophil counts are increased in the first 3 days after symptom onset in stroke patients, and this is associated with larger final IVs (on computed tomography and magnetic resonance imaging) and increased stroke severity. 27 Because stroke is associated with platelet activation, which we monitored by the heightened platelet adhesion in the brain, we determined whether Fpr2/3 deficiency changes the number of total, immature, and mature platelets and the level of activation within these platelet populations before and after stroke. Although we noted no change in platelet count resulting from stroke or between genotypes, we investigated this further using thiazole orange, a nucleic acid intercalating dye that has previously been used to detect and quantify immature platelets (which contain more RNA than their mature counterparts) in both humans 28 and mice 29 to assess the number of both mature and immature circulating platelets and the level of activation within these populations (by using the antibody [JONA] that recognizes the activated conformation of the murine glycoprotein IIb/IIIa integrin on the platelet surface). 19 These data 
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confirmed that the relative proportions of immature versus mature platelets did not change and that the level of activation within these populations was also unchanged. These observations demonstrate that the effects of our MCAo/R on platelet activation are local, whereas levels of circulating platelets and their maturity are not affected. The BBB is a critical guardian of communication between the periphery and the brain 30 and was compromised to a greater degree in the ipsilateral side compared with WT mice, suggesting that Fpr2/3, either directly or indirectly, preserves BBB permeability. This concurs with previous observations in which this receptor has been shown to be involved in the maintenance of BBB structure and function by downregulating RhoA GTPase activity after binding of AnxA1 and, in so doing, enabled the organization of the interendothelial cell tight and adherens junctions. 30 Overexpression of proinflammatory cytokines is another important component of the neuroinflammatory response. The precise concoction of proinflammatory cytokines deployed during I/R is variable, especially when assessed in the brain and not the periphery. We found an increase in IL-6 in I/R animals, which is in keeping with clinical data (>10 pg/mL in patients) and can correlate with poor clinical outcomes. 31 We measured higher levels of TNFα and IL-1β after cerebral I/R (heightened in the Fpr2/3 −/− mice). These cytokines not only attract leukocytes into ischemic sites, promoting tissue necrosis, but also can damage the microvascular endothelium, disrupt the BBB, and accelerate the formation of cerebral edema. We also found low IL-10 levels in both plasma and brain homogenates in the Fpr2/3 −/− mice. This is fitting with the clinical situation in which stroke patients with lower plasma concentrations (<6 pg/mL) of IL-10 deteriorated within 48 hours of stroke. 32 Having assessed that Fpr2/3 −/− mice are more susceptible to the macroscopic and microscopic effects of cerebral I/R, we proposed that targeting of Fpr2/3 with pharmacological interventions might prove beneficial. Indeed treatment of mice with AnxA1 or ATL administered at the start of reperfusion corroborated this hypothesis because many of the parameters under analysis were reduced. Coadministration of AnxA1 or ATL with the Fpr pan-antagonist Boc2 elicited an abrogation of their protective responses. Interestingly, responses observed after pharmacological blockade of the Fpr2/3 receptor (ie, administration of Boc2 alone) were not as pronounced as those observed with the genetic ablation of Fpr2/3 (ie, using Fpr2/3 −/− mice). This type of response is not unusual and has been observed in other studies. 33 However, although the dose of Boc2 used in our study has been used previously, 11, 20 the differences in response could be related to the dose of Boc2 administered (ie, sufficient to block the receptors but insufficient to initiate an exaggerated inflammatory response). Furthermore, the results from the Fpr2/3 −/− mice suggest that Fpr2/3 plays a more dominant role in controlling the vascular reactivity to ensure adequate counterregulation of the inflammatory response during MCAo/R. Thus, genetic ablation of Fpr2/3 results in a heightened inflammatory response, one that is exacerbated compared with exogenous administration of Boc2.
It has long been known that neutrophil, endothelial cell, and platelet interactions facilitate neutrophil recruitment and extravasation into brain parenchyma after stroke, 34 with postischemic neutrophil infiltration being a major component of the neuroinflammatory response. 35 Once in the brain, neutrophils damage tissue by releasing a number of detrimental substances such as oxygen free radicals, proteases, phospholipases, and neutrophil extracellular traps (decondensed DNA and proteases). 16, 34 Myeloperoxidase activity is a marker of neutrophil activity. In this study, we found it to be upregulated in the brain of WT mice and further exacerbated in brain homogenates from Fpr2/3 −/− mice, suggesting that the absence of this G protein-coupled receptor removes an endogenous tonic control on neutrophil influx and hence a sharp increase was observed after I/R injury. This is in keeping with studies in which Fpr2/3 agonists (especially LXA 4 and its derivatives) are able to decrease myeloperoxidase levels. This could be because lipoxins are able to inhibit neutrophil migration, 35 enhance neutrophil apoptosis, 36 and in some cases suppress reactive oxygen species production. 37 Growing evidence suggests that platelet-derived microparticles 38 amplify leukocyte activation and transmigration. Augmented plasma levels of TXB 4 after I/R suggest amplified platelet activation, which was markedly increased in FPR2/3 −/− mice. Previous reports of NPA formation in inflammation have shown that neutrophils bound to the endothelium secondarily capture platelets and that NPA formation and platelet activation are increased in ischemic stroke and are involved in the pathogenesis of stroke. 39 However, interestingly, our findings demonstrated for the first time that NPAs formed in the cerebral microcirculation in animals after I/R were significantly less in Fpr2/3 −/− compared with WT animals. It is known that neutrophils can use platelet-derived arachidonate to generate lipoxygenase products 33 and that NPA interactions use bidirectional transcellular routes to contribute to LXA 4 and ATL formation. Our results correlate with these findings and those of Brancaleone et al 33 in the mesenteric microcirculation that neutrophil/platelet interactions allow the production of LXA 4 . Here, we also found increased levels of ATL in both plasma and brain homogenates. That being said, we have not ruled out the possibility that the generation of other Fpr2/3 agonists could be contributing to the lipid mediator release. Some examples are resolvins 40 and humanin. 23 Further experiments will shed light on this.
Neutrophil accumulation is fundamental to acute inflammation. In response to tissue injury, circulating NPAs form for secondary capture. Counterregulation of acute inflammatory processes by specialized proresolving mediators is essential to restore homeostasis. 41 In peripheral organs such as the mesentery 33 and lung, 41 endogenous biosynthetic routes have been shown to be amplified during NPA formation to restrain these aggregates with counterregulatory circuits used to regulate the extent of the inflammation and to protect the tissue from further damage. Although this has been shown in systemic organs, the effect in the brain microcirculation was unknown. Using adoptive transfer of donor platelets into recipient mice and similar strategies, we concluded that in the cerebral microvasculature, neutrophil Fpr2/3 is important in forming aggregates with platelets. Although these findings are in line with previous findings in the systemic circulation (ie, mesentery) 33 after I/R injury, it would appear that in a lipopolysaccharide-induced lung injury model, neither neutrophil nor platelet Fpr2/3 alone is required for the formation of aggregates but rather that Fpr2/3 on both cell types is necessary to inhibit inflammation. 40 Additionally, it cannot be ruled out that the engagement of Fpr2/3 on other cell types such as endothelial cells 6 or microglia 42 could play a role in these findings. However, Fpr2/3 expression levels are very low in endothelial cells 23 and thus are unlikely to have an impact on the NPA response observed here.
Finally, to establish the clinical relevance of Fpr2/3 as a therapeutic target for stroke treatment and other neurovascular diseases such as multiple sclerosis 43 and Alzheimer disease, 44 we determined its impact in the pharmacological actions of ASA. This nonsteroidal anti-inflammatory drug has the ability to activate a number of mechanisms such as interfering with transcription factor of adenosine signaling 45 and the acetylation of cyclooxygenase-2 to block prostanoid synthesis. 45 Contact between platelets and neutrophils gives rise to the transcellular production of lipoxins and leukotrienes, 45 and even low-dose ASA administered to healthy volunteers is capable of producing bioactive levels of ATL. 33 Here, we showed that ASA administrated to mice with stroke could produce ATL, which triggers proresolving responses through the engagement of Fpr2/3.
Conclusions
Our results demonstrate that an absence of Fpr2/3 leads to an aberrant inflammatory response to stroke and that compounds targeting Fpr2/3 eg, AnxA1 , and ATL are powerful inhibitors of these inflammatory events. Our findings shed light on an endogenous biosynthetic circuit in neutrophils in which neutrophil Fpr2/3 controls NPA formation by rapid generation of ATL, which is engaged to restrain NPA formation and acute inflammation and to restore homeostasis in the brain. Furthermore, this study shows that Fpr2/3 is an attractive therapeutic target and that ATL and other potentially proresolving lipid mediators are attractive treatment option for patients with stroke, a disease that currently lacks any effective pharmacotherapies.
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SUPPLEMENTAL MATERIAL
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Supplemental Methods
Animals
All studies were done blinded and performed on adult male mice weighing 25-30g. Wild-type (WT) C57BL/6 mice were purchased from either Jackson Laboratory (Bar Harbor, ME, USA) or Charles River Limited (Margate, Kent, UK). In a separate set of experiments, mice were intraperitoneally (i.p.) treated with Aspirin (ASA. 150 mg/kg Sigma-Aldrich, Dorset, UK) 60 minutes (min) prior to I/R.
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Middle cerebral artery occlusion and reperfusion (MCAo)
As a cerebral I/R model, MCAo was performed as previously reported. 2 Briefly, mice were anaesthetized with i.p. injection of ketamine (150 mg/kg) and xylazine (7.5 mg/kg) and MCA was occluded for 60 min using a 6-nylon intraluminal filament (Doccol Corporation, Massachusetts, USA), followed by 4 h or 24 h of reperfusion. Sham-operated mice were subject to anesthesia and other surgical procedures without MCA occlusion and analyzed 5 h or 25 h after start of surgery.
Blood sampling and cell count
Mice were placed under a heat-lamp, and the tip of tail (~1mm) was cut with scissors, and heparinized capillary tubes were used to collect blood samples. Whole blood samples obtained from tail-vein bleed were used for measuring leukocytes (3% citric acid & 10% crystal violet) and platelet (1% buffered ammonium oxalate) counts with a hemocytometer.
Platelet and leukocyte labeling
Blood from donor mice was withdrawn in syringes prefilled with 85 mM sodium citrate, 62.2 mM citric acid, and 110 mM glucose (ACD buffer, Sigma-Aldrich). Platelet-rich plasma was obtained by centrifugation (118 × g, 8 min) before platelet isolation by centrifugation at 735 g for 10 min. Platelets were gently resuspended, counted, and labeled by using carboxyfluorescein succinimidyl ester (CFSE, 90 µM, 10 min, Sigma-Aldrich). After confirming absence of aggregates by light microscopy, 100 × 10 6 platelets in 120 µL saline were injected through the jugular vein of a recipient mouse over 5-minute infusion as previously described. This was followed by the continuous infusion of 0.02 % rhodamine 6G, which fluorescently labeled circulating leukocytes.
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Cerebral intravital fluorescence microscopy (IVM)
IVM was performed as previously described. 2 Briefly, mice were re-anaesthetized with i.p. injection of ketamine (150 mg/kg) and xylazine (7.5 mg/kg), and the jugular artery and vein cannulated to monitor mean arterial blood pressure (MABP), as well as for i.v. administration of rhodamine 6G and ex vivo labeled platelets. The head of each mouse was then fixed in a plastic frame in sphinx position. The left parietal bone was exposed by a midline skin incision, followed by a craniectomy (diameter: 2.5 mm) with a drill at 1 mm posterior from the bregma and 4 mm lateral from the midline. The dura mater was not cut because the fluorescent-labeled leukocytes were readily visualized. A 12 mm glass coverslip was placed over the craniectomy and the space between the glass and dura mater was filled with artificial cerebrospinal fluid (aCSF; Na 
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Infarct volume
After a 24 h reperfusion period, mice were killed and brains were immediately removed, placed into 4°C phosphate-buffered saline (PBS, Sigma-Aldrich) for 15 min; 2 mm coronal sections were then cut with a tissue cutter. The brain sections were stained with 2 % 2,3,5-triphenyltetrazolium chloride (TTC) in phosphate buffer at 37°C for 15 min and fixed by immersion in 10% formaldehyde. 2 The stained sections were photographed and the digitized images of each brain section (and the infarcted area) were quantified using a computerized image analysis program (NIH 1.57 Image Software).
Neurological score
The functional consequences of cerebral I/R injury were evaluated by using a five-point neurological deficit score (0, no deficit; 1, failure to extend right paw; 2, circling to the right; 3, falling to the right; and 4, unable to walk spontaneously) 2 and were assessed in a blinded fashion. A maximal score of 4 could be assigned to each experimental animal.
Blood-Brain Barrier (BBB) Dysfunction
BBB permeability was assessed using the Evans blue (EB) extravasation, as described previously. 4 Briefly, a 2 % solution of EB (Sigma-Aldrich) was injected (4 mL/kg) i.v. Twenty-four hours later, blood was obtained for plasma collection and brains were harvested after transcardial perfusion with PBS for 5 min. The cerebral hemispheres and the plasma were homogenized in 50 % trichloroacetic acid, sonicated, and then centrifuged. The supernatant was diluted with ethanol and the concentrations of Evans blue in brain tissue and plasma were measured using a fluorescence spectrophotometer
